Summary: Lucid News speaks to Berra Yazar-Klosinski, Ph.D., MAPS Deputy Director and Head of Research Development and Regulatory Affairs, to learn more about the promising results from the long-term follow-up of six Phase 2 clinical trials of MDMA-assisted psychotherapy for the treatment of PTSD, systemic challenges that impact the diversity of the trials, and potential solutions to address access within psychedelic research. “We are committed to ensuring those who are underserved by our current healthcare system can participate in psychedelic therapy clinical trials,” says Yazar-Klosinski. “We still have a long way to go, and we are listening and doing what we can.”
Originally appearing here.
